Pyc Therapeutics Limited · ASX:PYC

Pyc Therapeutics — Phylogica — Investor Presentation (October 2013)

36 slides from Pyc Therapeutics's investor presentation, Oct 28, 2013

1. Slide 1: Harnessing Biodiversity for Peptide Therapeutics

   BREAKTHROUGH PEPTIDE THERAPEUTICS For personal use only Harnessing Biodiversity for Peptide Therapeutics October 2013 1

2. Slide 2: Corporate Introduction

   For personal use only Corporate Introduc.on

3. Slide 3: About Phylogica

   About Phylogica § Listed on Australian Stock Exchange in 2005 (ASX:PYC) For personal use only § Provides pepFde drug discovery services to the PharmaceuFcal industry § Owns a unique proprietary class of pepFde therapeuFcs (Phylomers®) § Broad IP estate with mulFple granted patents from 12 patent

4. Slide 4: Corporate overview

   Corporate overview § OperaFons in Perth, Australia For personal use only § Phylomer® pepFde libraries derived from most structurally diverse genomes § ‘Discovery Alliance’ business model for rapid revenue growth – Already received >$5.8M in commi^ed revenue in less than 4 years § Alliances with

5. Slide 5: Top-10 shareholders

   Top-­‐10 shareholders Position Holder name Shares % of issued For personal use only 1 Hockings Family Office 35,251,999 7.55% 2 Telethon Institute 20,605,501 4.41% 3 Andrew Swift 18,186,088 3.90% 4 Ascent BioMedical Ventures 16,949,152 3.63% 5 Paul Watt 16,758,730 3.59% 6 John Jelbert 11,492,398 2.4

6. Slide 6: Phylogica's current partnerships span a wide range of areas

   Phylogica’s current partnerships span a wide a range of areas For personal use only Cell penetrating peptides Phylogica CNS Delivery Antimicrobials Vaccines

7. Slide 7: Phylogica owns an entire class of peptide drug

   Phylogica owns an en.re class of pep.de drug § Exclusive ownership enables PYC to control access to Phylomer pepFdes. For personal use only § Analogous to ownership of rights to an oil field by and oil exploraFon company § This control allows licensing of rights to access the resource (like licens

8. Slide 8: Business Model: focus on discovery alliances

   Business Model: focus on discovery alliances § Fee-­‐for-­‐service screening against third party targets For personal use only § Building long-­‐term value through milestones and royalFes § Increasing deal economics and share of down-­‐stream value § Opportunity to subsidise internal development

9. Slide 9: Collaborations and commercial partners validate Phylomers

   Collabora.ons and commercial partners validate Phylomers § Janssen (Johnson & Johnson) – CollaboraFon to discover cell-­‐penetra.ng pep.des in Dec 2011 – MulF-­‐product agreement with minimum of 18 months research funding For personal use only – CollaboraFon expanded in Jan 2013, expanded scope in

10. Slide 10: Recent highlights

    Recent highlights § Expanded Janssen collaboraFon on pepFde-­‐drug conjugates to include For personal use only downstream biological validaFon of opFmal hits § Filed patent on new technology to discover cell-­‐penetraFng pepFdes that escape the endosome (Endosomal Escape Trap) § Constructed secon

11. Slide 11: Leadership and experience

    Leadership and experience For personal use only Dr Richard Hopkins – CEO • Doctorate from Murdoch University, Western Australia • Over 10 years commercial biotech experience • Overseen development of the Phylomer plamorm. • Over 20 publicaFons and inventor on 13 patent families Dr Paul Wa) – CSO • C

12. Slide 12: Leadership and Experience: Non-executive Directors

    Leadership and Experience: Non-­‐execu.ve Directors Dr Douglas Wilson -­‐ Chairman For personal use only § Former Senior Vice-­‐President, Medicine for Boehringer Ingelheim § Overseen mulFple drugs at all phases of development § Overseen many drugs successfully to the market in the USA Mr Bruce M

13. Slide 13: Phylomers derive from parts of biodiverse proteins

    Phylomers derive from parts of biodiverse proteins § Encoded from >35 biodiverse genomes derived from environments such For personal use only volcanoes, geysers and undersea vents § Phylomer libraries contain >400 billion disFnct pepFde sequences § Pre-­‐selected by evoluFon to allow survival, su

14. Slide 14: Sourced from different evolutionary species

    Sourced from different evolu.onary species § Worlds richest source of diverse natural secondary and terFary structures For personal use only Watt PM (2006), Nature Biotechnology, Vol 24 (2):177-83 14 14

15. Slide 15: Harvesting structural diversity for drug discovery

    For personal use only Harves.ng structural diversity for drug discovery Wa) 2009 Future Medicinal Chemistry. 1 (2) 257-­‐265. § Phylomer libraries comprise thousands of unique structural families § Phylomer screens allow the target to ‘choose’ the scaffold from thousands of folds 15

16. Slide 16: Uniquely integrated capabilities of Phylomer platform

    For personal use only Uniquely integrated capabili.es of Phylomer plaZorm Phylogica’s unique discovery platform: § Discover and validate new therapeutic targets found inside cells Citron (Phenomica) (Citron Homology Domain) § Develop therapeutic peptide leads against such targets § Deliver therap

17. Slide 17: Majority of Therapeutic Targets are Intracellular

    Majority of Therapeu.c Targets are Intracellular Cellular distribuFon of therapeuFc targets considered ‘druggable’ For personal use only (1,700-­‐3,000 targets) • Small Molecules (10%) • AnFbodies • Scaffolds • PepFdes • Small Molecules Undrugged (70%) Phylomers Phylomers Phylomers 17

18. Slide 18: Cell penetrating Phylomers (CPPs): gaining access to intracellular targets

    Cell penetra.ng Phylomers (CPP’s): gaining access to intracellular targets For personal use only Phylomers can expand the druggable landscape by >10-­‐fold!! 18

19. Slide 19: Discovery of Phylomer-derived Cell Penetrating Peptides

    For personal use only Discovery of Phylomer-­‐derived Cell Penetra.ng Pep.des

20. Slide 20: Multiple classes of validated Phylomer CPPs

    For personal use only Mul.ple classes of validated Phylomer CPPs Length Phylomer Comments Charge (aa) BEN_1079 • Cationic TAT-like sequence. 18 +9 • Similar to gp41 transmembrane protein from SIV. BEN_0805 26 +3 • Facilitates fusion between viral and endosomal membranes. • Putative transposase from

21. Slide 21: Summary of 'First Generation' CPP screens

    Summary of ‘First Genera.on’ CPP screens § Phylomers represent a rich source of novel CPPs For personal use only § IdenFfied different classes of CPPs § Libraries can be used to capture CPPs with a range of cell penetraFng mechanisms § Currently developing Second Genera.on CPP discovery plaZorm –

22. Slide 22: Nature's Modular Solution to Cell Penetration

    Nature’s Modular Solu.on to Cell Penetra.on § The modular structure of Bacterial Toxins provides a template for improving For personal use only efficiency of cell penetraFon and cargo delivery § Modularity enable Phylomers to ‘Plug-­‐n-­‐Play’ with exisFng therapies Cell Membrane Receptor Binding Tr

23. Slide 23: Endosomal Escape Trap for efficient CPP Discovery

    Endosomal Escape Trap for efficient CPP Discovery § CPP delivery requires 3 independent acFviFes – Cell binding For personal use only – Endosomal Uptake – Endosomal Release § Phylogica’s endosome escape trap for capture of CPPs which efficiently deliver biologics cargoes into cell and out of endosome

24. Slide 24: Phylomer-mediated delivery of RBD cargo to mammalian cells

    Phylomer-­‐mediated delivery of RBD cargo to mammalian cells For personal use only § Increased binding/uptake of FITC-­‐labeled PYC_RBD fusions at 2µM RBD TAT_RBD 0031_RBD 0167_RBD 24

25. Slide 25: Phylogica Differentiation, Deals and Growth Strategy

    For personal use only Phylogica Differen.a.on, Deals and Growth Strategy

26. Slide 26: Demand for novel approaches to peptide drug discovery

    Demand for novel approaches to pep.de drug discovery For personal use only Find new structures within proteins selected Limited success with BREAKTHROUGH PEPTIDE THERAPEUTICS by evolution for diversity, stability and biological compatibility conven>onal approaches has increased demand for novel appr

27. Slide 27: Phylomers: a versatile toolbox for drug discovery

    Phylomers: a vers.le toolbox for drug discovery: plaOorm validated in diverse areas For personal use only Intracellular Targets Extracellular Targets Phenotypic Screening Antimicrobial Phylomers Epitope Mapping Scaffold Discovery Novel Cell Penetrating Peptides Vaccines 27

28. Slide 28: Extensive intellectual property position

    Extensive intellectual property posi.on § Phylogica controls access to the Phylomer class of pepFde drug, allowing it to do license deals around access to pepFdes derived For personal use only from its libraries § Granted patents cover methods of making and screening Phylomer libraries and composi

29. Slide 29: Three overlapping strategic phases

    For personal use only Three overlapping strategic phases 1. Partnering: generate near-­‐term revenue from discovery alliances 2. Technological leadership: enhance plamorm through value-­‐adding upgrades 3. In-­‐house drug development: build value by advancing internal products Revenue Generation Tec

30. Slide 30: Anticipated technology validation milestones

    An.cipated technology valida.on milestones § Each milestone provides value-­‐adding enhancement to Phylomer plamorm For personal use only -­‐ Boosts our a^racFveness to discovery alliance partners and potenFal acquirers Technology Purpose Es.mated valida.on date Endosomal Escape Trap IdenFfying new

31. Slide 31: New Internal Discovery Program: MAP4K4

    New Internal Discovery Program: MAP4K4 § MAP4K4 is a criFcal regulator of muscle, inflammatory disease and of certain cancers For personal use only • eg. ovarian cancer, hepatocellular carcinoma, lung cancer, pancreaFc or prostate cancer § InhibiFon of MAP4K4 with siRNA inhibits growth of hepatocel

32. Slide 32: New Internal Discovery Program: Myc/Max

    New Internal Discovery Program: Myc/Max § The Myc genes are the most commonly upregulated oncogenes in cancer For personal use only § Validated PPI’s targets involving Myc family members: – cMyc/Max (lymphoma, lung breast cancer and colorectal cancer) and – MycN/Max (neuroblastoma) – Target alread

33. Slide 33: Anticipated commercial milestones

    An.cipated commercial milestones § Further Pharma deals around areas of experFse such as: For personal use only § Phenotypic screening for discovery and validaFon of new targets (Phenomica) § Efficient delivery of biologics by phylomer-­‐derived cell penetraFng pepFdes § Discovery of novel anFmicr

34. Slide 34: Phylogica vs. Peptidream

    Phylogica vs. Pep.dream § Both Phylogica and PepFdream own a proprietary source of pepFde drugs and both plamorms have potenFal to capture macrocyclic pepFdes § For personal use only PepFDream's PepFde Discovery Plamorm System enables incorporaFon of modified unnatural amino acids into pepFde libra

35. Slide 35: Summary

    Summary § Assembled and validated a world-­‐class pepFde drug discovery plamorm For personal use only § Patent protecFon on worlds largest source of naturally structured pepFdes and related screening technologies – priority to 2027 § Successfully validated ‘Alliance Model’ with four top 10 Pharma

36. Slide 36: Contact Details

    Dr. Richard Hopkins Contact Details Dr. Paul Wa` Chief Execu.ve Officer Chief Scien.fic Officer Tel: +61 8 9489 7777 Tel: +61 8 9489 7777 For personal use only Fax: +61 8 9489 7700 Fax: +61 8 9489 7700 Mobile: +61 405 656 868 Mobile: +61 421 550 213 richardh@phylogica.com paulw@phylogica.com www.phylogic

Phylogica — Investor Presentation (October 2013) on 6ix